➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Litigation Details for FEDERAL TRADE COMMISSION v. ABBVIE INC (E.D. Pa. 2014)

Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in FEDERAL TRADE COMMISSION v. ABBVIE INC
The small molecule drug covered by the patents cited in this case is ⤷  Free Forever Trial .


Date Filed Document No. Description Snippet Link To Document
2014-09-08 1 pharmaceutical composition patent relating to AndroGel, U.S. Patent No. 6,503,894 (the “’894 Patent”). To obtain this… this patent, Unimed and Besins were required by the U.S. Patent and Trademark Offlce (“PTO”) to significantly…. Aware of the patent’s narrow scope, Perrigo and Teva designed around the ’894 Patent, developing generic…while prosecuting the ’894 Patent before the PTO in order to obtain the ’894 Patent. Abeie Defendants and …their products infringe the ’894 Patent is without merit. ln the patent litigation, Teva counterclaimed External link to document
2015-08-25 118 7 Besins together hold U.S. Patent No. 6,503,894 (the “‘894 Patent”) for a popular brand-name testosterone…infringe GSK’s patent or that the patent was unenforceable. GSK responded by filing patent infringement…of the patent. The FTC alleges that Abbott, Unimed, and Besins initiated sham patent infringement…up its patent challenge by offering an early entry date for AndroGel, the subject of the patent litigation…the extent it was based on the settlement of the patent litigation. The External link to document
2015-12-13 145 Memorandum and/or Opinion Unimed”) and Besins obtained U.S. Patent No. 6,503,894 (“the ‘894 patent”) for the brand-name testosterone…referenced by name in the ‘894 patent. We do not opine on whether or not the ‘894 patent covers additional penetration…recent meeting with patent examiner and examiner’s decision regarding allowing patent.” The email was…a United States Patent and Trademark Office examiner to Mahoney concerning the patent application. …its patent claims were narrowed to a single penetration enhancer at the time it filed the patent infringement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.